文献速递药疹与重症皮肤不良反应

美国急性泛发性发疹性脓疱病患者的临床特征、疾病病程与结局

Clinical Characteristics, Disease Course, and Outcomes of Patients With Acute Generalized Exanthematous Pustulosis in the US.
PubMed 文献 · JAMA Dermatol · 2022-01-01

该研究回顾性分析了美国10个学术健康系统2000年1月1日至2020年7月31日间的340例急性泛发性发疹性脓疱病(AGEP)患者,采用EuroSCAR评分系统评估。多数为女性(62.9%)、白人(60.6%),疑因药物诱发者占85.6%,30天全因死亡率为3.5%,无死亡被认为由AGEP所致。

要点

  • AGEP起病急,中位潜伏期3天(IQR 1-9),常见诱因为抗菌药物。
  • 约半数患者(49.7%)出现体温≥38.0°C,85.1%出现绝对中性粒细胞增多。
  • 少数患者可发生肝酶升高(8.4%)或急性肾损伤(7.8%)。

核心结论

  • AGEP起病急,通常由近期抗菌药物暴露触发,少数患者可能伴肝或肾并发症,停用触发药物后可能改善或消退。

研究设计与样本

  • 回顾性病例系列评估,纳入美国10个学术健康系统2000年1月1日至2020年7月31日的340例患者,采用EuroSCAR评分系统回顾性评分,纳入评分符合很可能或确定AGEP且年龄≥18岁者。

主要发现

  • 340例患者中女性214例(62.9%)、白人206例(60.6%)、非西班牙裔239例(70.3%),平均(SD)年龄57.8(17.4)岁。
  • 310例中154例(49.7%)体温≥38.0°C,持续中位2天(IQR 1-4);309例中263例(85.1%)出现绝对中性粒细胞增多,161例(52.1%)出现绝对或相对嗜酸性粒细胞增多。
  • 疑似病因:药物291例(85.6%)、静脉造影剂7例(2.1%)、感染3例(0.9%)、未知39例(11.5%);单一药物明确的151例中,β-内酰胺类抗菌药63例(41.7%)、非β-内酰胺类抗菌药51例(33.8%)、抗惊厥药9例(6.0%)、钙通道阻滞剂5例(3.3%)。
  • 用药起始至AGEP发病中位时间3天(IQR 1-9);298例中25例(8.4%)出现天冬氨酸氨基转移酶和丙氨酸氨基转移酶急性升高,峰值中位6天(IQR 3-9);319例中25例(7.8%)发生急性肾功能不全,肌酐峰值中位在AGEP发病后4天(IQR 2-5)。
  • 治疗包括局部糖皮质激素277例(81.5%,单用或联用)、全身糖皮质激素109例(32.1%)、环孢素10例(2.9%)或仅支持治疗36例(10.6%);30天内全因死亡率3.5%(n=12),无一例死亡被认为由AGEP所致。

临床怎么用

  • 作者认为,停用触发药物可能使AGEP改善或消退。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Acute generalized exanthematous pustulosis (AGEP) is a rare, severe cutaneous adverse reaction associated with systemic complications. Currently available data are largely limited to small retrospective case series. OBJECTIVE: To describe the clinical characteristics, disease course, and outcomes of a heterogeneous group of patients with AGEP across the US. DESIGN, SETTING, AND PARTICIPANTS: A retrospective review of a case series of patients was conducted from January 1, 2000, through July 31, 2020. All 340 included cases throughout 10 academic health systems in the US were scored retrospectively using the EuroSCAR scoring system, and patients with a score corresponding to probable or definite AGEP and aged 18 years or older were included. MAIN OUTCOMES AND MEASURES: Patient demographic characteristics, clinical course, suspected causative agent, treatment, and short- and long-term outcomes. RESULTS: Most of the 340 included patients were women (214 [62.9%]), White (206 [60.6%]), and non-Hispanic (239 [70.3%]); mean (SD) age was 57.8 (17.4) years. A total of 154 of 310 patients (49.7%) had a temperature greater than or equal to 38.0 °C that lasted for a median of 2 (IQR, 1-4) days. Of 309 patients, 263 (85.1%) developed absolute neutrophilia and 161 patients (52.1%) developed either absolute or relative eosinophilia. Suspected causes of AGEP were medications (291 [85.6%]), intravenous contrast agents (7 [2.1%]), infection (3 [0.9%]), or unknown (39 [11.5%]). In 151 cases in which a single medication was identified, 63 (41.7%) were β-lactam antimicrobials, 51 (33.8%) were non-β-lactam antimicrobials, 9 (6.0%) were anticonvulsants, and 5 (3.3%) were calcium channel blockers. The median time from medication initiation to AGEP start date was 3 (IQR, 1-9) days. Twenty-five of 298 patients (8.4%) had an acute elevation of aspartate aminotransferase and alanine aminotransferase levels, with a peak at 6 (IQR, 3-9) days. Twenty-five of 319 patients (7.8%) experienced acute kidney insufficiency, with the median time to peak creatinine level being 4 (IQR, 2-5) days after the AGEP start date. Treatments included topical corticosteroids (277 [81.5%], either alone or in combination), systemic corticosteroids (109 [32.1%]), cyclosporine (10 [2.9%]), or supportive care only (36 [10.6%]). All-cause mortality within 30 days was 3.5% (n = 12), none of which was suspected to be due to AGEP. CONCLUSIONS AND RELEVANCE: This retrospective case series evaluation of 340 patients, the largest known study cohort to date, suggests that AGEP onset is acute, is usually triggered by recent exposure to an antimicrobial, may be associated with liver or kidney complications in a minority of patients, and that discontinuation of the triggering treatment may lead to improvement or resolution.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Creadore A, Desai S, Alloo A, et al. Clinical Characteristics, Disease Course, and Outcomes of Patients With Acute Generalized Exanthematous Pustulosis in the US. JAMA Dermatol. 2022. PMID: 34985493. doi:10.1001/jamadermatol.2021.5390

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。